Expanding clinical role of unique class III antiarrhythmic effects of sotalol
- 2 January 1990
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 65 (2) , 84-88
- https://doi.org/10.1016/0002-9149(90)90209-j
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Suppressant effects of conventional beta blockers and sotalol on complex and repetitive ventricular premature complexesThe American Journal of Cardiology, 1990
- When is QT prolongation antiarrhythmic and when is it proarrhythmic?The American Journal of Cardiology, 1989
- Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserinThe American Journal of Cardiology, 1989
- Cardiac Electrophysiologic Effects of Intravenous Ketanserin in HumansJournal of Cardiovascular Pharmacology, 1987
- Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.Circulation, 1985
- Antiarrhythmic and Antifibrillatory Actions of the Levo- and Dextrorotatory Isomers of SotalolJournal of Cardiovascular Pharmacology, 1984
- Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia.Circulation, 1984
- Comparative mechanisms of action of antiarrhythmic drugsAmerican Heart Journal, 1974
- The effect of amiodarone, a new anti‐anginal drug, on cardiac muscleBritish Journal of Pharmacology, 1970
- A third class of anti‐arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474British Journal of Pharmacology, 1970